Endocrinology Flashcards
What are the physiological causes of early morning hyperglycemia in insulin-dependent individuals?
Physiological increase in growth hormone levels in the early morning hours stimulates gluconeogenesis and leads to a subsequent increase in insulin demand that cannot be met in insulin-dependent patients, resulting in elevated blood glucose levels.
Diagnostic criteria for diabetes mellitus
Random blood glucose level >= 200mg/dL in patients with symptoms of hyperglycemia (ie. polydipsia, polyuria, polyphagia, unexplained weight loss) or hyperglycemic crisis
OR
>= 2 abnormal test results for hyperglycemia in asymptomatic individuals
Describe the oral glucose tolerance test
Measurement of fasting plasma glucose and blood glucose 2 hours after the consumption of 75g of glucose
Describe Hemoglobin A1C test
HbA1C test measures the concentration of glycated hemogloblin A1 in red blood cells (glucose in the blood binds to hemoglobin). HbA1C test measures the average blood glucose levels of the prior 8-12 weeks
Which conditions and treatments may alter HbA1C results?
Sickle cell trait
CKD
Increased RBC lifespan (e.g. iron and/or vitamin B12 deficiency, splenectomy, aplastic anemia
Heavy alcohol use
Decreased RBC lifespan (e.g. due to acute blood loss, sickle cell trait, thalassemia, G6PD deficiency, cirrhosis, hemolytic anemia, splenomegaly, antiretrovial drugs)
Increased erythropoiesis (EPO therapy, pregnancy, iron supplementation)
How often should you check HbA1C in a diabetic patient?
At least every 3-6 months
Fasting glucose level target in diabetes
80-130 mg/DL (4.4-7.2 mmol/L)
Contraindications for metformin
Severely impaired renal function (eGFR <30mL/minute/1.73m2)
Acute or chronic metabolic acidosis (including ketoacidosis)
Hypersensitivity to metformin
Name glucose dependent and glucose independent insulinotropic agents
Glucose-dependent: GLP1 agonists, DPP4 inhibitors
Glucose-independent: Sufonylureas, meglitinides
How do insulinotropic agents work?
Stimulate the secretion of insulin from pancreatic B cells - either stimulated by elevated blood glucose levels (postprandially) or irrespective of blood glucose levels (risk of hypoglycemia)
Common contraindications of antidiabetic drugs
T1DM
Pregnancy and breastfeeding (all contraindicated - should be substituted with human insulin)
Renal failure (if GFR<30ml/min DPP4 inhibitors, incretin mimetic drugs, meglitinides and thiazolidinediones may be administered)
Major surgery under general anesthesia
Acute conditions requiring hospitalisation (infections, organ failure)
Elective procedures associated with an increased risk of hypoglycemia (periods of fasting)
How do biguanides (metformin) work?
- Enhances effect of insulin
- Decreases hepatic gluconeogenesis and intestinal glucose absorption
- Increases peripheral insulin sensitivity which increases peripheral glucose uptake and glycolysis
- Reduces LDL, increases HDL
Clinical characteristics of metformin:
- Lowers HbA1C by 1.2-2% over 3 months
- Weight loss
- No risk of hypoglycemia
- Reduces risk of macroangiopathic complications
Side effects of metformin
- Metformin associated lactic acidosis
- GI symtoms (N+V, diarrhoea, vomiting, adominal pain, flatulence
- Severe symptoms: muscle cramps, hyperventilation, apathy, disorientation, coma
How do thiazolidinediones (glitazones) work?
Increased storage of fatty acids in adipocytes, decreased free fatty acids in circulation, increased glucoe utilisation and decreased hepatic glucose production
Side effects of glitazones
Increased risk of heart failure
Increased risk of fractures (osteoporosis)
Fluid retention and oedema
Weight gain
Rosiglitazone: Increased risk of CV complications like cardiac infarction or death
How do sulfonylureas work?
Block ATP-sensitive potassium channels of the pancreatic B cells -> depolarisation of the cell membrane -> calcium influx -> insulin secretion
Contraindications to sulfonylureas
Beta blockers (can mask hypoglycemic symptoms while lowering serum glucose levels)
Severe CV comorbidity
Obesity
Sulfonamide allergy
Liver and kidney failure
Names of sulfonylureas
Chlorpropamide
Tolbutamide
Glyburide
Glipizide
Glimepiride
How do glucagon-like peptide 1 receptor agonists (incretin mimetics) work?
Incretin mimetic drugs bind to the GLP-1 receptors and are resistant to degradation by DPP4 enzyme -> increased insulin secretion, decreased glucagon secretion, slow gastric emptying (increased feeling of satiety, decreased weight)
Side effects of GLP1 receptor agonists
N+V
Strong feeling of satiety
Pancreatitis and potentially pancreatic cancer
Contraindications for GLP1 receptor agonists
GI motility disorders
Chronic pancreatitis or a family history of pancreatic tumors
Personal or family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN 2)
How do Dipeptidyl peptidase-4 inhibitors (gliptins) work?
Indirectly increase the endogenous incretin effect by inhibiting the DPP-4 that breaks down GLP-1 -> increased insulin secretion -> decreased glucagon secretion, delayed gastric emptying
Side effects of DPP-4 inhibitors
GI symptoms
Arthralgia
Nasopharyngitis and URTI
Increased feelings of satiety
Urinary infections (mild)
Increased risk of pancreatitis
Worsening renal function, acute renal failure
Headaches, dizziness
How do SGLT2 inhibitors (glifozins) work?
Reversible inhibition of SGLT2 in the proximal tubule of the kidney -> decreased glucose reabsorption in the PCT of the kidney -> glycosuria and polyuria
Side effects of SGLT2 inhibitors
UTIs, genital infections (vulvovaginal candidiasis, balantitis) due to glucosuria
Dehydration, weight loss, orthostatic hypotension
Severe diabetic ketoacidosis
Describe a hyperosmolar hyperglycemic state
Condition primarily seen in T2DM due to extreme hyperglycemia. Unlike in DKA, there is some insulin available to suppress fat breakdown so ketosis does not result, rather, severe hyperglycemia (>600mg/dL) may develop
Clinical manifestations of hyperosmolar hyperglycemic state
Polyuria, polydipsia, nausea, vomiting, volume depletion and eventually mental status changes and coma
Describe diabetic ketoacidosis
Primarily seen in patients with T1DM
Caused by insufficient insulin levels (often secondary to acute infection).
Hyperglycemia (usually 300-600 mg/dL)
Macrovascular complications of diabetes
Atherosclerosis - related more to metabolic risk factors including obesity, dyslipidemia, arterial HTN rather than hyperglycemia
Manifestations:
- Coronary heart disease
- Cerebrovascular disease
- Peripheral artery disease
- Monckeberg arteriosclerosis
- Gangrene
Microvascular complications of diabetes
Diabetic nephropathy
Diabetic retinopathy, glaucoma
Diabetic neuropathy including diabetic gastroparesis
Diabetic foot
Pathophysiology of microvascular disease
Chronic hyperglycemia -> nonenzymatic glycation of proteins and lipids -> thickening of the basal membrane with progressive function impairment and tissue damage